BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7859883)

  • 1. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
    Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure.
    Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Tura S; Papa G
    Cancer; 1994 Sep; 74(6):1792-800. PubMed ID: 8082082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
    Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
    Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapy.
    Reisbach G; Kamp T; Welzl G; Geiz C; Abedinpour Fariborz ; Lodri A; Kaboth W; Dörmer P; Nerl C
    Br J Haematol; 1996 Mar; 92(4):907-12. PubMed ID: 8616084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.
    Paradisi R; Vicenti R; Macciocca M; Seracchioli R; Rossi S; Fabbri R
    Fertil Steril; 2016 Oct; 106(5):1176-1182. PubMed ID: 27430206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiphospholipid antibodies: prevalence, clinical significance and correlation to cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma.
    Stasi R; Stipa E; Masi M; Oliva F; Sciarra A; Perrotti A; Zaccari G; Papa G
    Thromb Haemost; 1993 Oct; 70(4):568-72. PubMed ID: 8115979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine profile during high-dose rhG-CSF therapy in severe congenital neutropenia.
    Shitara T; Yugami S; Ijima H; Sotomatu M; Kuroume T
    Am J Hematol; 1994 Jan; 45(1):58-62. PubMed ID: 7504401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.
    Gorschlüter M; Bohlen H; Hasenclever D; Diehl V; Tesch H
    Ann Oncol; 1995 May; 6(5):477-82. PubMed ID: 7545429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
    Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
    Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma.
    Ho AD; Haas R; Wulf G; Knauf W; Ehrhardt R; Heilig B; Körbling M; Schulz G; Hunstein W
    Blood; 1990 Jan; 75(1):203-12. PubMed ID: 2104762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
    Fabre-Guillevin E; Tabrizi R; Coulon V; Monnereau A; Eghbali H; Soubeyran I; Soubeyran P
    Leuk Lymphoma; 2006 Apr; 47(4):603-11. PubMed ID: 16690518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
    Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
    Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of the measurement of serum soluble IL-2 receptor alpha chain levels in clinical monitoring of non-Hodgkin lymphoma].
    Setoyama Y; Imai J; Ishikawa T; Sakaida H; Takaori-Kondo A; Kawamata S; Uchiyama T
    Rinsho Byori; 1994 Aug; 42(8):834-42. PubMed ID: 7933620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin's lymphoma].
    Sciarra A; Stasi R; Stipa E; Masi M; Oliva F; Olivieri M; Perrotti A; Zaccari G; Amadori S; Papa G
    Recenti Prog Med; 1995 Feb; 86(2):57-62. PubMed ID: 7754173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-colony-stimulating factor induces increased serum levels of soluble interleukin 2 receptors preceding engraftment in autologous bone marrow transplantation.
    Dreger P; Grelle K; Eckstein V; Suttorp M; Müller-Ruchholtz W; Löffler H; Schmitz N
    Br J Haematol; 1993 Jan; 83(1):7-13. PubMed ID: 7679589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
    Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.